Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 484

1.

Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis.

Fox RJ, Coffey CS, Conwit R, Cudkowicz ME, Gleason T, Goodman A, Klawiter EC, Matsuda K, McGovern M, Naismith RT, Ashokkumar A, Barnes J, Ecklund D, Klingner E, Koepp M, Long JD, Natarajan S, Thornell B, Yankey J, Bermel RA, Debbins JP, Huang X, Jagodnik P, Lowe MJ, Nakamura K, Narayanan S, Sakaie KE, Thoomukuntla B, Zhou X, Krieger S, Alvarez E, Apperson M, Bashir K, Cohen BA, Coyle PK, Delgado S, Dewitt LD, Flores A, Giesser BS, Goldman MD, Jubelt B, Lava N, Lynch SG, Moses H, Ontaneda D, Perumal JS, Racke M, Repovic P, Riley CS, Severson C, Shinnar S, Suski V, Weinstock-Guttman B, Yadav V, Zabeti A; NN102/SPRINT-MS Trial Investigators.

N Engl J Med. 2018 Aug 30;379(9):846-855. doi: 10.1056/NEJMoa1803583.

PMID:
30157388
2.

Cladribine tablets added to IFN-β in active relapsing MS: The ONWARD study.

Montalban X, Leist TP, Cohen BA, Moses H, Campbell J, Hicking C, Dangond F.

Neurol Neuroimmunol Neuroinflamm. 2018 Jul 11;5(5):e477. doi: 10.1212/NXI.0000000000000477. eCollection 2018 Sep.

3.

Clinical outcomes in patients with relapsing-remitting multiple sclerosis who switch from natalizumab to delayed-release dimethyl fumarate: A multicenter retrospective observational study (STRATEGY).

Cohan SL, Moses H, Calkwood J, Tornatore C, LaGanke C, Smoot KE, Meka V, Okwuokenye M, Hotermans C, Mendoza JP, Mann MK, Meltzer LA.

Mult Scler Relat Disord. 2018 May;22:27-34. doi: 10.1016/j.msard.2018.02.028. Epub 2018 Feb 26.

4.

Infliximab for the treatment of CNS sarcoidosis: A multi-institutional series.

Gelfand JM, Bradshaw MJ, Stern BJ, Clifford DB, Wang Y, Cho TA, Koth LL, Hauser SL, Dierkhising J, Vu N, Sriram S, Moses H, Bagnato F, Kaufmann JA, Ammah DJ, Yohannes TH, Hamblin MJ, Venna N, Green AJ, Pawate S.

Neurology. 2017 Nov 14;89(20):2092-2100. doi: 10.1212/WNL.0000000000004644. Epub 2017 Oct 13.

5.

The missing, the short, and the long: Exploring the borderland between psychiatry and neurology.

Moses H 3rd.

Ann Neurol. 2017 Sep;82(3):493. doi: 10.1002/ana.25034. No abstract available.

PMID:
28858398
6.

Development of Aggressive Pancreatic Ductal Adenocarcinomas Depends on Granulocyte Colony Stimulating Factor Secretion in Carcinoma Cells.

Pickup MW, Owens P, Gorska AE, Chytil A, Ye F, Shi C, Weaver VM, Kalluri R, Moses HL, Novitskiy SV.

Cancer Immunol Res. 2017 Sep;5(9):718-729. doi: 10.1158/2326-6066.CIR-16-0311. Epub 2017 Aug 3.

7.

Pharmacologic Inhibition of β-Catenin With Pyrvinium Inhibits Murine and Human Models of Wilms Tumor.

Polosukhina D, Love HD, Moses HL, Lee E, Zent R, Clark PE.

Oncol Res. 2017 Nov 2;25(9):1653-1664. doi: 10.3727/096504017X14992942781895. Epub 2017 Jul 10.

8.

Inhibition of TGF-β with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression.

Biswas S, Guix M, Rinehart C, Dugger TC, Chytil A, Moses HL, Freeman ML, Arteaga CL.

J Clin Invest. 2017 Mar 1;127(3):1116. doi: 10.1172/JCI93333. Epub 2017 Mar 1. No abstract available.

9.

Functional KRAS mutations and a potential role for PI3K/AKT activation in Wilms tumors.

Polosukhina D, Love HD, Correa H, Su Z, Dahlman KB, Pao W, Moses HL, Arteaga CL, Lovvorn HN 3rd, Zent R, Clark PE.

Mol Oncol. 2017 Apr;11(4):405-421. doi: 10.1002/1878-0261.12044. Epub 2017 Mar 15.

10.

TGF-β, Bone Morphogenetic Protein, and Activin Signaling and the Tumor Microenvironment.

Pickup MW, Owens P, Moses HL.

Cold Spring Harb Perspect Biol. 2017 May 1;9(5). pii: a022285. doi: 10.1101/cshperspect.a022285. Review.

PMID:
28062564
11.

PI3K Inhibition Reduces Mammary Tumor Growth and Facilitates Antitumor Immunity and Anti-PD1 Responses.

Sai J, Owens P, Novitskiy SV, Hawkins OE, Vilgelm AE, Yang J, Sobolik T, Lavender N, Johnson AC, McClain C, Ayers GD, Kelley MC, Sanders M, Mayer IA, Moses HL, Boothby M, Richmond A.

Clin Cancer Res. 2017 Jul 1;23(13):3371-3384. doi: 10.1158/1078-0432.CCR-16-2142. Epub 2016 Dec 21. Erratum in: Clin Cancer Res. 2018 Aug 1;24(15):3782.

12.

Quantifying Geographic Variation in Health Care Outcomes in the United States before and after Risk-Adjustment.

Rosenberg BL, Kellar JA, Labno A, Matheson DH, Ringel M, VonAchen P, Lesser RI, Li Y, Dimick JB, Gawande AA, Larsson SH, Moses H 3rd.

PLoS One. 2016 Dec 14;11(12):e0166762. doi: 10.1371/journal.pone.0166762. eCollection 2016.

13.

TβRIII Expression in Human Breast Cancer Stroma and the Role of Soluble TβRIII in Breast Cancer Associated Fibroblasts.

Jovanović B, Pickup MW, Chytil A, Gorska AE, Johnson KC, Moses HL, Owens P.

Cancers (Basel). 2016 Nov 4;8(11). pii: E100.

14.

Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosis.

Fox RJ, Coffey CS, Cudkowicz ME, Gleason T, Goodman A, Klawiter EC, Matsuda K, McGovern M, Conwit R, Naismith R, Ashokkumar A, Bermel R, Ecklund D, Koepp M, Long J, Natarajan S, Ramachandran S, Skaramagas T, Thornell B, Yankey J, Agius M, Bashir K, Cohen B, Coyle P, Delgado S, Dewitt D, Flores A, Giesser B, Goldman M, Jubelt B, Lava N, Lynch S, Miravalle A, Moses H, Ontaneda D, Perumal J, Racke M, Repovic P, Riley C, Severson C, Shinnar S, Suski V, Weinstock-Gutman B, Yadav V, Zabeti A.

Contemp Clin Trials. 2016 Sep;50:166-77. doi: 10.1016/j.cct.2016.08.009. Epub 2016 Aug 10.

15.

Update on reconstructive options for nasal Mohs defects 1.5 cm or less.

Moses HA, Woodard CR.

Curr Opin Otolaryngol Head Neck Surg. 2016 Aug;24(4):300-8. doi: 10.1097/MOO.0000000000000265. Review.

PMID:
27389925
16.

Biomarker Tests for Molecularly Targeted Therapies--The Key to Unlocking Precision Medicine.

Lyman GH, Moses HL.

N Engl J Med. 2016 Jul 7;375(1):4-6. doi: 10.1056/NEJMp1604033. Epub 2016 Jun 1. No abstract available.

PMID:
27353537
17.

The Discovery and Early Days of TGF-β: A Historical Perspective.

Moses HL, Roberts AB, Derynck R.

Cold Spring Harb Perspect Biol. 2016 Jul 1;8(7). pii: a021865. doi: 10.1101/cshperspect.a021865. Review.

18.

Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection.

Lehmann BD, Jovanović B, Chen X, Estrada MV, Johnson KN, Shyr Y, Moses HL, Sanders ME, Pietenpol JA.

PLoS One. 2016 Jun 16;11(6):e0157368. doi: 10.1371/journal.pone.0157368. eCollection 2016.

19.

Genotype tunes pancreatic ductal adenocarcinoma tissue tension to induce matricellular fibrosis and tumor progression.

Laklai H, Miroshnikova YA, Pickup MW, Collisson EA, Kim GE, Barrett AS, Hill RC, Lakins JN, Schlaepfer DD, Mouw JK, LeBleu VS, Roy N, Novitskiy SV, Johansen JS, Poli V, Kalluri R, Iacobuzio-Donahue CA, Wood LD, Hebrok M, Hansen K, Moses HL, Weaver VM.

Nat Med. 2016 May;22(5):497-505. doi: 10.1038/nm.4082. Epub 2016 Apr 18.

20.

Biomarker Tests for Molecularly Targeted Therapies: Laying the Foundation and Fulfilling the Dream.

Lyman GH, Moses HL.

J Clin Oncol. 2016 Jun 10;34(17):2061-6. doi: 10.1200/JCO.2016.67.3160. Epub 2016 Apr 11.

PMID:
27069080
21.

The impact of bone morphogenetic protein 4 (BMP4) on breast cancer metastasis in a mouse xenograft model.

Ampuja M, Alarmo EL, Owens P, Havunen R, Gorska AE, Moses HL, Kallioniemi A.

Cancer Lett. 2016 Jun 1;375(2):238-244. doi: 10.1016/j.canlet.2016.03.008. Epub 2016 Mar 9.

PMID:
26970275
22.

Opportunity Cost of Surgical Management of Craniomaxillofacial Trauma.

Moses H, Powers D, Keeler J, Erdmann D, Marcus J, Puscas L, Woodard C.

Craniomaxillofac Trauma Reconstr. 2016 Mar;9(1):76-81. doi: 10.1055/s-0035-1566160. Epub 2015 Oct 28.

23.

Fibroblast-Mediated Collagen Remodeling Within the Tumor Microenvironment Facilitates Progression of Thyroid Cancers Driven by BrafV600E and Pten Loss.

Jolly LA, Novitskiy S, Owens P, Massoll N, Cheng N, Fang W, Moses HL, Franco AT.

Cancer Res. 2016 Apr 1;76(7):1804-13. doi: 10.1158/0008-5472.CAN-15-2351. Epub 2016 Jan 27.

24.

Bone morphogenetic protein signaling promotes tumorigenesis in a murine model of high-grade glioma.

Hover LD, Owens P, Munden AL, Wang J, Chambless LB, Hopkins CR, Hong CC, Moses HL, Abel TW.

Neuro Oncol. 2016 Jul;18(7):928-38. doi: 10.1093/neuonc/nov310. Epub 2015 Dec 18.

25.

Depletion of Carcinoma-Associated Fibroblasts and Fibrosis Induces Immunosuppression and Accelerates Pancreas Cancer with Reduced Survival.

Özdemir BC, Pentcheva-Hoang T, Carstens JL, Zheng X, Wu CC, Simpson TR, Laklai H, Sugimoto H, Kahlert C, Novitskiy SV, De Jesus-Acosta A, Sharma P, Heidari P, Mahmood U, Chin L, Moses HL, Weaver VM, Maitra A, Allison JP, LeBleu VS, Kalluri R.

Cancer Cell. 2015 Dec 14;28(6):831-833. doi: 10.1016/j.ccell.2015.11.002. Epub 2015 Dec 14. No abstract available.

26.

Deletion of the BMP receptor BMPR1a impairs mammary tumor formation and metastasis.

Pickup MW, Hover LD, Guo Y, Gorska AE, Chytil A, Novitskiy SV, Moses HL, Owens P.

Oncotarget. 2015 Sep 8;6(26):22890-904.

27.

Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer.

Nagathihalli NS, Castellanos JA, Shi C, Beesetty Y, Reyzer ML, Caprioli R, Chen X, Walsh AJ, Skala MC, Moses HL, Merchant NB.

Gastroenterology. 2015 Dec;149(7):1932-1943.e9. doi: 10.1053/j.gastro.2015.07.058. Epub 2015 Aug 7.

28.

Preoperative Lumbar Drain Use During Acoustic Neuroma Surgery and Effect on CSF Leak Incidence.

Crowson MG, Cunningham CD 3rd, Moses H, Zomorodi AR, Kaylie DM.

Ann Otol Rhinol Laryngol. 2016 Jan;125(1):63-8. doi: 10.1177/0003489415597917. Epub 2015 Aug 3.

PMID:
26239000
29.

Small molecule inhibitor of the bone morphogenetic protein pathway DMH1 reduces ovarian cancer cell growth.

Hover LD, Young CD, Bhola NE, Wilson AJ, Khabele D, Hong CC, Moses HL, Owens P.

Cancer Lett. 2015 Nov 1;368(1):79-87. doi: 10.1016/j.canlet.2015.07.032. Epub 2015 Jul 30.

30.

A Murine Model of K-RAS and β-Catenin Induced Renal Tumors Expresses High Levels of E2F1 and Resembles Human Wilms Tumor.

Yi Y, Polosukhina D, Love HD, Hembd A, Pickup M, Moses HL, Lovvorn HN 3rd, Zent R, Clark PE.

J Urol. 2015 Dec;194(6):1762-70. doi: 10.1016/j.juro.2015.04.090. Epub 2015 Apr 29.

31.

TGFβ signaling in myeloid cells regulates mammary carcinoma cell invasion through fibroblast interactions.

Shaw AK, Pickup MW, Chytil A, Aakre M, Owens P, Moses HL, Novitskiy SV.

PLoS One. 2015 Jan 28;10(1):e0117908. doi: 10.1371/journal.pone.0117908. eCollection 2015.

32.

Age- and pregnancy-associated DNA methylation changes in mammary epithelial cells.

Huh SJ, Clement K, Jee D, Merlini A, Choudhury S, Maruyama R, Yoo R, Chytil A, Boyle P, Ran FA, Moses HL, Barcellos-Hoff MH, Jackson-Grusby L, Meissner A, Polyak K.

Stem Cell Reports. 2015 Feb 10;4(2):297-311. doi: 10.1016/j.stemcr.2014.12.009. Epub 2015 Jan 22.

33.

The anatomy of medical research: US and international comparisons.

Moses H 3rd, Matheson DH, Cairns-Smith S, George BP, Palisch C, Dorsey ER.

JAMA. 2015 Jan 13;313(2):174-89. doi: 10.1001/jama.2014.15939.

PMID:
25585329
34.

Planning the future of neurology: crisis or opportunity.

Martin JB, Moses H 3rd.

JAMA Neurol. 2015 Feb;72(2):141-2. doi: 10.1001/jamaneurol.2014.3448. No abstract available.

PMID:
25437247
35.

Recognizing and overcoming potential barriers to oral medications for MS.

Moses H Jr.

J Clin Psychiatry. 2014 Oct;75(10):e28. doi: 10.4088/JCP.13037nr3c.

36.

Attenuated transforming growth factor beta signaling promotes metastasis in a model of HER2 mammary carcinogenesis.

Novitskiy SV, Forrester E, Pickup MW, Gorska AE, Chytil A, Aakre M, Polosukhina D, Owens P, Yusupova DR, Zhao Z, Ye F, Shyr Y, Moses HL.

Breast Cancer Res. 2014 Oct 4;16(5):425. doi: 10.1186/s13058-014-0425-7.

37.

Concerted loss of TGFβ-mediated proliferation control and E-cadherin disrupts epithelial homeostasis and causes oral squamous cell carcinoma.

Andl T, Le Bras GF, Richards NF, Allison GL, Loomans HA, Washington MK, Revetta F, Lee RK, Taylor C, Moses HL, Andl CD.

Carcinogenesis. 2014 Nov;35(11):2602-10. doi: 10.1093/carcin/bgu194. Epub 2014 Sep 18.

38.

BMPR2 loss in fibroblasts promotes mammary carcinoma metastasis via increased inflammation.

Pickup MW, Hover LD, Polikowsky ER, Chytil A, Gorska AE, Novitskiy SV, Moses HL, Owens P.

Mol Oncol. 2015 Jan;9(1):179-91. doi: 10.1016/j.molonc.2014.08.004. Epub 2014 Aug 23.

39.

Role of TGF-β signaling in generation of CD39+CD73+ myeloid cells in tumors.

Ryzhov SV, Pickup MW, Chytil A, Gorska AE, Zhang Q, Owens P, Feoktistov I, Moses HL, Novitskiy SV.

J Immunol. 2014 Sep 15;193(6):3155-64. doi: 10.4049/jimmunol.1400578. Epub 2014 Aug 15.

40.

Inhibition of BMP signaling suppresses metastasis in mammary cancer.

Owens P, Pickup MW, Novitskiy SV, Giltnane JM, Gorska AE, Hopkins CR, Hong CC, Moses HL.

Oncogene. 2015 May 7;34(19):2437-49. doi: 10.1038/onc.2014.189. Epub 2014 Jul 7.

41.

Transforming growth factor beta receptor type III is a tumor promoter in mesenchymal-stem like triple negative breast cancer.

Jovanović B, Beeler JS, Pickup MW, Chytil A, Gorska AE, Ashby WJ, Lehmann BD, Zijlstra A, Pietenpol JA, Moses HL.

Breast Cancer Res. 2014 Jul 1;16(4):R69. doi: 10.1186/bcr3684.

42.

Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival.

Özdemir BC, Pentcheva-Hoang T, Carstens JL, Zheng X, Wu CC, Simpson TR, Laklai H, Sugimoto H, Kahlert C, Novitskiy SV, De Jesus-Acosta A, Sharma P, Heidari P, Mahmood U, Chin L, Moses HL, Weaver VM, Maitra A, Allison JP, LeBleu VS, Kalluri R.

Cancer Cell. 2014 Jun 16;25(6):719-34. doi: 10.1016/j.ccr.2014.04.005. Epub 2014 May 22. Erratum in: Cancer Cell. 2015 Dec 14;28(6):831-3.

43.

ALCAM/CD166 is a TGF-β-responsive marker and functional regulator of prostate cancer metastasis to bone.

Hansen AG, Arnold SA, Jiang M, Palmer TD, Ketova T, Merkel A, Pickup M, Samaras S, Shyr Y, Moses HL, Hayward SW, Sterling JA, Zijlstra A.

Cancer Res. 2014 Mar 1;74(5):1404-15. doi: 10.1158/0008-5472.CAN-13-1296. Epub 2014 Jan 2.

44.

The anatomy of health care in the United States.

Moses H 3rd, Matheson DH, Dorsey ER, George BP, Sadoff D, Yoshimura S.

JAMA. 2013 Nov 13;310(18):1947-63. doi: 10.1001/jama.2013.281425. Review.

PMID:
24219951
45.

The roles of TGFβ in the tumour microenvironment.

Pickup M, Novitskiy S, Moses HL.

Nat Rev Cancer. 2013 Nov;13(11):788-99. doi: 10.1038/nrc3603. Epub 2013 Oct 17. Review.

46.

Stromally derived lysyl oxidase promotes metastasis of transforming growth factor-β-deficient mouse mammary carcinomas.

Pickup MW, Laklai H, Acerbi I, Owens P, Gorska AE, Chytil A, Aakre M, Weaver VM, Moses HL.

Cancer Res. 2013 Sep 1;73(17):5336-46. doi: 10.1158/0008-5472.CAN-13-0012. Epub 2013 Jul 15.

47.

Bone Morphogenetic Proteins stimulate mammary fibroblasts to promote mammary carcinoma cell invasion.

Owens P, Polikowsky H, Pickup MW, Gorska AE, Jovanovic B, Shaw AK, Novitskiy SV, Hong CC, Moses HL.

PLoS One. 2013 Jun 28;8(6):e67533. doi: 10.1371/journal.pone.0067533. Print 2013.

48.

Diagnostic and therapeutic aspects of Hashimoto's encephalopathy.

Olmez I, Moses H, Sriram S, Kirshner H, Lagrange AH, Pawate S.

J Neurol Sci. 2013 Aug 15;331(1-2):67-71. doi: 10.1016/j.jns.2013.05.009. Epub 2013 Jun 5.

PMID:
23759502
49.

Acute outcome of stent therapy for coarctation of the aorta: results of the coarctation of the aorta stent trial.

Ringel RE, Vincent J, Jenkins KJ, Gauvreau K, Moses H, Lofgren K, Usmani K.

Catheter Cardiovasc Interv. 2013 Oct 1;82(4):503-10. doi: 10.1002/ccd.24949. Epub 2013 May 15.

PMID:
23592408
50.

Funding for biomedical research--reply.

Moses H 3rd, Dorsey ER.

JAMA. 2013 Mar 27;309(12):1228-9. doi: 10.1001/jama.2013.1346. No abstract available.

PMID:
23532234

Supplemental Content

Support Center